Cai Beilei, Nickman Nancy A, Gaffney David K
Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City, Utah 84112-0258, USA.
J Pain Palliat Care Pharmacother. 2013 Mar;27(1):28-34. doi: 10.3109/15360288.2012.757267. Epub 2013 Feb 8.
Bone is the third most common organ affected by neoplastic metastases, and about 70% of patients with breast cancer or prostate cancer that develop metastases will have osseous involvement. As part of a multi-pronged approach to pain management in these patients, external beam radio therapy (EBRT) continues to be a mainstay of treatment for metastatic bone pain. This article reviews the role of radiation therapy in palliative management strategies for patients with bone metastases, including the clinical and cost-effectiveness of single fraction (SFRT) versus multiple fraction (MFRT) EBRT in pain relief. Studies indicate that SFRT is more cost-effective than MFRT, yet both are clinically effective in pain management. Therefore, EBRT use retains an important place among analgesia, bone modifying agents, chemotherapy, and hormone therapy in improving quality of life (QoL) and reducing morbidity from metastatic bone pain.
骨骼是受肿瘤转移影响的第三大常见器官，约70%发生转移的乳腺癌或前列腺癌患者会出现骨转移。作为这些患者疼痛管理多管齐下方法的一部分，外照射放疗（EBRT）仍然是转移性骨痛治疗的主要手段。本文综述了放射治疗在骨转移患者姑息治疗策略中的作用，包括单次分割（SFRT）与多次分割（MFRT）EBRT在缓解疼痛方面的临床效果和成本效益。研究表明，SFRT比MFRT更具成本效益，但两者在疼痛管理方面均具有临床疗效。因此，在改善生活质量（QoL）和降低转移性骨痛发病率方面，EBRT在镇痛、骨改良剂、化疗和激素治疗中仍占有重要地位。
